Cerus (NASDAQ:CERS – Get Free Report) and Delcath Systems (NASDAQ:DCTH – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.
Insider and Institutional Ownership
78.4% of Cerus shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 5.3% of Cerus shares are owned by insiders. Comparatively, 19.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Cerus has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
Profitability
This table compares Cerus and Delcath Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cerus | -3.23% | -10.44% | -3.42% |
| Delcath Systems | 6.05% | 5.56% | 4.98% |
Earnings and Valuation
This table compares Cerus and Delcath Systems”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cerus | $226.57 million | 1.77 | -$15.63 million | ($0.03) | -66.17 |
| Delcath Systems | $109.96 million | 6.50 | $2.70 million | $0.16 | 128.44 |
Delcath Systems has lower revenue, but higher earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and price targets for Cerus and Delcath Systems, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cerus | 1 | 1 | 3 | 0 | 2.40 |
| Delcath Systems | 0 | 1 | 2 | 1 | 3.00 |
Cerus currently has a consensus price target of $5.25, suggesting a potential upside of 164.48%. Delcath Systems has a consensus price target of $29.33, suggesting a potential upside of 42.74%. Given Cerus’ higher probable upside, research analysts clearly believe Cerus is more favorable than Delcath Systems.
Summary
Delcath Systems beats Cerus on 10 of the 15 factors compared between the two stocks.
About Cerus
Cerus Corporation is a biomedical products company focused on improving the safety of blood components used for transfusions. Its primary offering is the INTERCEPT Blood System, which uses a pathogen-reduction process designed to inactivate a broad range of viruses, bacteria, parasites and white blood cells in donated blood components. INTERCEPT is used to process platelet and plasma components. Cerus also develops related processing devices and supplies for blood centers and transfusion services.
About Delcath Systems
Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.
